Name: ERNAW Cash Flow - Ernexa Therapeutics Operating Cash & FCF | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Operating Cash Flow, Investing Cash Flow, Financing Cash Flow, Capital Expenditures, Free Cash Flow, Dividends Paid, Stock Buybacks, Net Change in Cash

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ERNAW - Ernexa Therapeutics Inc.

USD | NASDAQ | Healthcare

ERNAW Cash Flow - Ernexa Therapeutics Operating Cash & FCF | Ledgeburg

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Net Income
Net Income	(5.5)	(1.5)	(1.2)	(3.1)	(8.2)	(5.8)	(26.6)	(5.5)	(6.6)	(6.2)	(5.6)	(4.5)	(5.4)	(4.5)	(7.3)	(3.4)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010
Net Income
Net Income	(11.4)	(14.1)	(44.5)	(21.7)	(24.6)	(122.5)	(7.3)	(2.0)	(0.3)	(1.1)	(2.9)	(7.2)	(5.0)	(1.1)	(1.0)	(3.4)	(0.4)
Cash From Operating Activities
Depreciation & Amortization	0.1	0.1	0.1	0.1	0.2	0.1	0.1	2.9	2.8	2.3	2.9	3.1	2.7	2.8
Cash From Investing Activities
Capital Expenditures	-	0.0	0.4	0.0	0.3	0.2	0.0	0.1	0.6	0.7	0.4	1.0	0.8	1.1	1.2
Cash From Financing Activities
Debt Issued	-	-	-	-	-	-	3.1	-	4.0	0.1	2.5	6.7	6.0	-	-	-
Change In Cash & Equivalents
Effects Of Exchange Rate Changes	-	-	-	-	-	-	-	0.0	(0.1)	0.1	0.0	(0.1)	(0.1)	(0.1)
Free Cash Flow
Free Cash Flow	-	(7.1)	(16.2)	(20.4)	(21.3)	(23.6)	(8.1)	2.6	0.7	(0.2)	(0.4)	(5.2)	(7.2)	0.6	0.9	(1.0)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Cash From Investing Activities
Capital Expenditures	0.0	-	-	-	-	-	-	-	0.1	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.2	-	-	-	0.1	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Divestitures	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	-
Purchase Of Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales Of Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash From Investing Activities	(0.0)	-	-	-	-	-	-	-	(0.1)	-	-	-	0.0	-	-

Cash From Financing Activities
Debt Issued	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt Repaid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock Issuance	10.5	-	-	-	-	-	-	-	-	-	-	-	0.0	-	-	-	12.0
Common Stock Repurchased	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash From Financing Activities	9.6	-	-	-	2.3	-	-	-	1.4	-	-	-	0.0	-	-

Free Cash Flow
Free Cash Flow	(2.3)	-	-	-	-	-	-	-	(3.8)	-	-	-	(6.0)	-	-	-	(5.5)	-	-	-	(3.4)	-	-	-	(1.9)	-	-	-	0.7	-	-	-	(0.3)	-	-	-	(0.6)	-	-	-
Free Cash Flow To Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cash Flow Statement